Despite the growing popularity and promising outcomes of GLP-1 RAs as weight-loss adjuncts, there is a need for an examination of the available evidence to determine the safety and efficacy of these pharmacotherapies in patients with PCOS [23-26]. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.